Capecitabine in advanced gastric cancer.

Abstract

Since the routine introduction of chemotherapy for advanced gastric cancer in the early 1990 s, median survival for gastric cancer has improved from 3 months, with best supportive care alone, to > 11 months in recently reported Phase III trials of triplet chemotherapy. Capecitabine is an orally-active fluoropyrimidine, which is selectively metabolised to fluorouracil in tumour cells. The combinations of platinum compounds and capecitabine have been evaluated in two recent, large, Phase III trials demonstrating non-inferiority in efficacy compared with platinum plus continuous infusion fluorouracil. In view of the convenience and flexibility of patients in adjusting dosage when encountering toxicities, capecitabine is replacing continuous infusion fluorouracil as the backbone of combination chemotherapy in advanced gastric cancer patients. Future trials evaluating biologicals are now incorporating capecitabine combinations as control arms in both advanced disease and peri-operative settings in gastric cancer.

• Authors: Alicia Okines, Ian Chau, David Cunningham
• Journal: Expert opinion on pharmacotherapy (Expert Opin Pharmacother) Vol. 8 Issue 16 Pg. 2851-61 (Nov 2007) ISSN: 1744-7666 [Electronic] England
• PMID: 17956204 (Publication Type: Journal Article, Review)

Chemical References

• Antimetabolites, Antineoplastic
• Prodrugs
• Deoxycytidine
• Capecitabine
• Fluorouracil

Topics

• Antimetabolites, Antineoplastic (adverse effects, pharmacokinetics, therapeutic use)
• Capecitabine
• Clinical Trials as Topic
• Deoxycytidine (adverse effects, analogs & derivatives, pharmacokinetics, therapeutic use)
• Drug Approval
• Fluorouracil (adverse effects, analogs & derivatives, pharmacokinetics, therapeutic use)
• Humans
• Prodrugs (adverse effects, pharmacokinetics, therapeutic use)
• Stomach Neoplasms (drug therapy)